Emergency Surgery Unit, Department of Surgical Science, University of Cagliari, SS 554, Km 4,500, 09042, Monserrato, Cagliari, Italy.
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
World J Emerg Surg. 2024 Sep 10;19(1):30. doi: 10.1186/s13017-024-00558-3.
Recent studies suggest that low-molecular-weight heparin (LMWH) may play a role in mitigating the severity of acute pancreatitis (AP). This systematic review and meta-analysis aims to synthesise existing evidence on the effectiveness and safety of LMWH in the treatment of moderately-severe and severe AP.
This systematic review and meta-analysis was conducted in accordance with the 2020 update of the PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. The systematic search was conducted in MEDLINE, the Cochrane Central Register of Controlled Trials, Scopus, and EMBASE, covering studies published up to February 2024. Randomised controlled trials (RCTs) and observational studies (n-RCTs) that reported the differences in the outcomes of AP for patients receiving LMWH in addition to the standard treatment (Intervention), compared to patients managed by standard treatment without LMWH (Control) were eligible. A random-effects model was used to calculate the pooled relative risk (RR) and mean differences (MD) with the corresponding 95% CI.
Thirteen studies were included in the meta-analysis, all published between 2004 and 2022. Eight studies were RCTs, and five were n-RCTs. Data from 13,709 patients (6.971 Interventions and 6.738 Controls) were analysed. The comparison of Intervention and Control groups showed the superiority of LMWH to standard treatments in terms of overall mortality (RR = 0.44, 95% CI = 0.31; 0.64, P < 0.0001, I = 51%), acute necrotic collections (RR = 0.24, 95% CI = 0.09; 0.62, P = 0.003, I = 0%), and organ failure (RR = 0.67, 95% CI = 0.48; 0.93, P = 0.02, I = 78%). The Intervention group showed superior outcomes compared with the Control group for gastrointestinal bleeding (RR = 0.64, 95% CI = 0.44; 0.94, P = 0.02, I = 0%), length of hospital stay (MD= - 6.08, 95% CI = - 10.08; - 2.07, P = 0.003, I = 98%), need for operative interventions (RR = 0.50, 95% CI = 0.29; 0.87, P = 0.01, I = 61%), and vascular thrombosis (RR = 0.43, 95% CI = 0.31; 0.61, P < 0.00001, I = 0%).
Moderate to high-quality evidence suggests that early intervention with LMWH could improve the prognosis of non-mild AP in terms of mortality, organ failure, and decreased incidence of vascular thrombosis. In light of our findings, integrating LMWH into the treatment regimen for moderate-severe to severe AP is advocated.
最近的研究表明,低分子量肝素(LMWH)可能在减轻急性胰腺炎(AP)的严重程度方面发挥作用。本系统评价和荟萃分析旨在综合现有关于 LMWH 治疗中度和重度 AP 的疗效和安全性的证据。
本系统评价和荟萃分析按照 2020 年 PRISMA 指南更新和 Cochrane 干预系统评价手册进行。系统检索了 MEDLINE、Cochrane 对照试验中心注册库、Scopus 和 EMBASE,涵盖了截至 2024 年 2 月发表的研究。纳入了报告接受 LMWH 加标准治疗(干预组)与接受标准治疗无 LMWH(对照组)的 AP 患者结局差异的随机对照试验(RCT)和观察性研究(非随机对照试验)。使用随机效应模型计算汇总相对风险(RR)和均数差值(MD)及其相应的 95%置信区间(CI)。
共有 13 项研究纳入荟萃分析,均发表于 2004 年至 2022 年之间。其中 8 项为 RCT,5 项为非随机对照试验。共分析了 13709 名患者(6971 名干预组和 6738 名对照组)的数据。干预组与对照组相比,LMWH 治疗在总体死亡率(RR=0.44,95%CI=0.31;0.64,P<0.0001,I=51%)、急性坏死性积聚(RR=0.24,95%CI=0.09;0.62,P=0.003,I=0%)和器官衰竭(RR=0.67,95%CI=0.48;0.93,P=0.02,I=78%)方面具有优越性。与对照组相比,干预组在胃肠出血(RR=0.64,95%CI=0.44;0.94,P=0.02,I=0%)、住院时间(MD=-6.08,95%CI=-10.08;-2.07,P=0.003,I=98%)、需要手术干预(RR=0.50,95%CI=0.29;0.87,P=0.01,I=61%)和血管血栓形成(RR=0.43,95%CI=0.31;0.61,P<0.00001,I=0%)方面的结局更优。
中高质量证据表明,早期应用 LMWH 可能改善非轻症 AP 的预后,降低死亡率、器官衰竭和血管血栓形成的发生率。基于我们的发现,建议将 LMWH 纳入中重度至重度 AP 的治疗方案中。